Kaituo Pharmaceutical announced that the Chinese Phase II clinical trial of the self-developed novel proteolytic chimeric compound GT20029 targeting androgen receptors to treat acne has read top-line data. According to the data, the phase II clinical trial successfully reached the main study end point. The results were statistically significant and clinically significant, and the efficacy, safety and pharmacokinetic characteristics were excellent, and the recommended dose for the phase III clinical trial was determined to be 0.5%.

Kaituo Pharmaceutical announced that the Chinese Phase II clinical trial of the self-developed novel proteolytic chimeric compound GT20029 targeting androgen receptors to treat acne has read top-line data. According to the data, the phase II clinical trial successfully reached the main study end point. The results were statistically significant and clinically significant, and the efficacy, safety and pharmacokinetic characteristics were excellent, and the recommended dose for the phase III clinical trial was determined to be 0.5%.